Effect of Ascorbic Acid on Postoperative Acute Kidney Injury in Coronary Artery Bypass Graft Patients: A Pilot Study
Keywords:ascorbic acid, vitamin C, acute kidney injury, coronary artery bypass grafting, cardiopulmonary bypass
Background: Even minor postoperative reductions in renal function influence the outcome of cardiac surgery. The mechanisms of postoperative renal injury in cardiac surgery are multifactorial and include ischemia-reperfusion injury. The study investigates the effect of the antioxidant ascorbic acid on the postoperative acute kidney injury after elective CABG surgery.
Methods: A prospective randomized single-center trial was conducted in on-pump coronary artery bypass patients. The patients in the ascorbic acid group received 2 grams of ascorbic acid 24 hours and 2 hours preoperatively and 1 gram twice daily five days after the surgery. Postoperatively, the subjects were monitored for renal dysfunction and
Results: 100 patients were included, with 50 patients in each study group. The groups were well matched for baseline demographics, preoperative medications, comorbidities, and had similar intraoperative characteristics. The incidence of postoperative acute kidney injury in the ascorbic acid group was 16% and 14% in the control group (P = .779). The groups also did not differ in peak postoperative serum creatinine
(83  µmol/L versus 83  µmol/L; P = .434), the lowest postoperative creatinine clearance (96.40 ± 35.78 mL/min versus 90.89 ± 36.18 mL/min; P = .766), and time from surgery to the onset of peak postoperative serum creatinine
(1.64 ± 1.34 days versus 1.92 ± 1.54 days; P = .393). There was no dialysis required in any patient.
Conclusion: The results of this study did not demonstrate a significant protective effect of ascorbic acid on the incidence of postoperative acute renal injury in elective on-pump CABG patients.
Antonic M, Gersak B. 2007. Renal function after port access and median sternotomy mitral valve surgery. Heart Surg Forum 10:E401-7.
Bjordahl PM, Helmer SD, Gosnell DJ, Wemmer GE, O’Hara W, Milfeld DJ. 2012. Perioperative supplementation with ascorbic acid does not prevent atrial fibrillation in coronary artery bypass graft patients. Am J Surg 204:862-7.
Bove T, Calabro MG, Landoni G, Aletti G, Marino G, Crescenzi G. 2004. The incidence and risk of acute renal failure after cardiac surgery. J Cardiothorac Vasc Anesth 18:442-5.
Briguori C, Airoldi F, D’Andrea D, et al. 2007. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation 115:1211-7.
Brown JR, Kramer RS, Coca SG, Parikh CR. 2010. Duration of acute kidney injury impacts long-term survival after cardiac surgery. Ann Thorac Surg 90:1142-9.
Cockcroft DW, Gault MH. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
Eslami M, Sattarzadeh Badkoubeh R, et al. 2007. Oral ascorbic acid in combination with beta-blockers is more effective than beta-blockers alone in the prevention of atrial fibrillation after coronary artery bypass grafting. Tex Heart Inst J 34:268-4.
Findik O, Aydin U, Baris O, et al. 2016. Preoperative low serum albumin levels increase the requirement of renal replacement therapy after cardiac surgery. Heart Surg Forum 19:E123-7.
Gardner TJ, Spray TL, eds. Operative Cardiac Surgery. 5th ed. London: Arnold; 2004.
Hobson CE, Yavas S, Segal MS, et al. 2009. Acute kidney injury is associated with increased long-term mortality after cardiothoracic surgery. Circulation 119:2444–53.
Korantzopoulos P, Kolettis TM, Kountouris E, et al. 2005. Oral vitamin C administration reduces early recurrence rates after electrical cardioversion of persistent atrial fibrillation and attenuates associated inflammation. Int J Cardiol 102:321-6.
Kouchoukos NT, Blackstone EH, Hanley FL, Kirklin JK. Kirklin/Barrat-Boyes Cardiac Surgery. 4th ed. Philadelphia: Elsevier; 2013.
Kramer RS, Herron CR, Groom RC, Brown JR. 2015. Acute kidney injury subsequent to cardiac surgery. JECT 47:16-28.
Lameire NH, Vanholder R. 2004. Pathophysiology of ischemic acute renal failure. Best Pract Res Clin Anaesthesiol 18:21-36.
Lassnigg A, Schmidlin D, Mouhieddine M, et al. 2004. Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: a prospective cohort study. J Am Soc Nephrol 15:1597-605.
Liano F, Pascual J. 1996. Epidemiology of acute renal failure: a prospective, multicenter, community-based study. Madrid acute renal failure study group. Kidney International 50:811-8.
Melethil S, Mason WD, Chian-Jo C. 1986. Dose-dependent absorption and excretion of vitamin C in humans. Int J Pharm 31:83-9.
Mehta RL, Kellum JA, Shah SV, et al. 2007. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 11:R31.
Myles PS, Scheinkestel C. 1993. Renal failure after cardiac surgery: Pathophysiology, prevention and treatment. As J Cardiac Thorac Surg 2:140-4.
Nashef SAM, Roques F, Sharples LD, et al. 2012. EuroSCORE II. Eur J Cardiothorac Surg 41:734-45.
National Kidney Foundation. 2002. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Part 4. Definition and Classification of Stages of Chronic Kidney Disease. Am J Kidney Dis 39:S46-75.
Ozcan AV, Sacar M, Aybek H, et al. 2007. The effects of iloprost and vitamin C on kidney as a remote organ after ischemia/reperfusion of lower extremities. J Surg Research 140:20-6.
Rababa’h AM, Deo SV, Altarabsheh SE, et al. 2016. N-acetyl cysteine therapy does not prevent renal failure in high-risk patients undergoing open-heart surgery. Heart Surg Forum 19:E16-22.
Rydén L, Ahnve S, Bell M, Hammar N, Ivert T, Holzmann MJ. 2012. Acute kidney injury following coronary artery bypass grafting: early mortality and postoperative complications. Scand Cardiovasc J 46:114-20.
Sadat U, Usman A, Gillard JH, Boyle JR. 2013. Does ascorbic acid protect against contrast-induced acute kidney injury in patients undergoing coronary angiography: a systematic review with meta-analysis of randomized, controlled trials. J Am Coll Cardiol 62:2167-75.
Tekeli Kunt A, Parlar H, Findik O, Duzyol C, Baris O, Balci C. 2016. The influence of metabolic syndrome on acute kidney injury occurrence after coronary artery bypass grafting. Heart Surg Forum 19:E099-103.
Trof RJ, Di Maggio F, Leemreis J, Groeneveld AB. 2006. Biomarkers of acute renal injury and renal failure. Shock 26:245-53.
Zhou L, Chen H. 2012. Prevention of contrast-induced nephropathy with ascorbic acid. Intern Med 51:531-5.
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).